NR1I2 and tuberculosis: Therefore, to fill this gap and elucidate the role of pharmacogenetics in RIF exposure and the potential effect on the development of anti-TB treatment-related hepatotoxicity, this study aimed to investigate (a) the relationship between SNPs detected in the set of the genes (AADAC, SLCO1B1, SLCO1B3, ABCB1, and NR1I2) and RIF PK parameters; and (b) the relationship between the detected SNPs and the development of anti-TB treatment-associated DILI in Latvian patients with pulmonary tuberculosis (PTB).